503A bulks-list tracker
This is a free tracker of an FDA vote that could change what compounding pharmacies are allowed to make. On July 23-24, 2026 the FDA's Pharmacy Compounding Advisory Committee votes on seven peptides for the 503A bulks list (the list of bulk substances compounding pharmacies may compound from). The vote is advisory, and formal FDA rulemaking is still required before any of these can be legally compounded. Here is where each one stands, and how to get your supplier documentation ready now.
What the vote actually is
PCAC hears nominators, takes public comment, deliberates, and votes a recommendation to the FDA. It is advice, not a rule.
Whether the vote is favorable or not, adding a substance to the 503A bulks list requires formal FDA rulemaking afterward. Until that is final, it is not compoundable.
Acting on a vote as if it were permission is how an operator ends up holding product they cannot legally sell. The smart play is getting education and documentation ready first.
The seven peptides
Source: FDA Pharmacy Compounding Advisory Committee. Status is updated from the public record. This is an informational tracker, not legal advice, confirm the current status with primary FDA sources before acting.
Stay ahead of it
We will email you when the committee votes and when the FDA moves on rulemaking for any of the seven. No spam, just the regulatory signal.
Get verification-ready now
These peptides are sourced as bulk drug substances. The day they become compoundable, the paperwork behind every lot, an FDA-registered source, a complete and consistent COA, and a record you can hand a board within one business day, is what stands between you and a finding. Get it in order before you need it.
Confirm and document that your bulk supplier is FDA-registered, with the registration on file, not just claimed.
Identity (mass spec), purity, and, for a parenteral peptide, sterility and endotoxin, present and internally consistent, tied to the exact lot.
Source-chain and lot-specific records you can produce on request, the kind state boards are starting to require within one business day.
Veritura verifies that documentation is real, complete, and consistent, and attaches a per-lot proof your prescribers and buyers can verify themselves.
Track the vote here, and have your documentation verified before rulemaking lands, not after.
This page is an informational tracker of a public FDA advisory-committee process. It is not legal, regulatory, medical, or compounding advice, and not a representation that any peptide is legal, safe, effective, approved, or appropriate to compound or use. A PCAC vote is a recommendation only; substances are added to the 503A bulks list through formal FDA rulemaking. Confirm current status with primary FDA sources, and consult qualified counsel before acting. Veritura performs independent document diligence only.